| Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ) |
|
|
| |
| • Company Description |
| Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
Number of Employees: 270 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $15.55 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,049,696 shares |
| Shares Outstanding: 86.14 (millions) |
| Market Capitalization: $1,339.51 (millions) |
| Beta: 0.72 |
| 52 Week High: $22.50 |
| 52 Week Low: $8.58 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
5.57% |
3.71% |
| 12 Week |
60.47% |
45.77% |
| Year To Date |
17.63% |
10.56% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
730 Third Avenue 9th Floor
-
New York,NY 10017
USA |
ph: 781-419-1400
fax: 781-419-1420 |
ir@syndax.com |
http://www.syndax.com |
|
|
| |
| • General Corporate Information |
Officers
Michael A. Metzger - Chief Executive Officer and Director
Dennis G. Podlesak - Chairman
Keith A. Goldan - Chief Financial Officer
Martin H. Huber - Director
Jennifer Jarrett - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87164F105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/04/25
|
|
Share - Related Items
Shares Outstanding: 86.14
Most Recent Split Date: (:1)
Beta: 0.72
Market Capitalization: $1,339.51 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.73 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.20 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 27.29% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/04/25 |
|
|
|
| |
